This is a randomized controlled trial of a whole food, plant-based (WFPB) dietary intervention among women with metastatic breast or endometrial cancer.
This is a randomized controlled trial of a whole food, plant-based (WFPB) dietary intervention among women with metastatic breast or endometrial cancer. It is designed to explore whether this dietary intervention is sustainable in this population for 26 weeks and whether improvements in quality of life and cardiometabolic health demonstrated in a previous study are sustained. If so, this study will gather information to know whether these benefits translate into reduced overall mortality and cancer markers when compared with a control group that is matched for time and attention but does not implement dietary change. The intervention consists of a whole food plant-based dietary program, group education and individual coaching/visits while the control group gets general wellness group education and individual visits while maintaining their usual diet.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
60
Regular Diet with Cancer-Related Wellness Education and Support
Whole Food, Plant-Based Diet with Behavioral Education and Support
Mean Change in Dietary Adherence at 13 and 26 Weeks
Dietary adherence is assessed by study personnel using pre-specified criteria. Participants are considered "adherent" if ≥80% of total calories are consumed from 'on-plan' foods. A single adherence score is calculated as the percentage of calories consumed from on-plan foods, averaged over the assessment period. Higher scores indicate greater adherence.
Time frame: 13 weeks, 26 weeks
Mean Change in Participant Retention at 13 and 26 Weeks
Retention is calculated as the percentage of consented participants who provide both baseline and post-intervention assessments. Higher percentages indicate better retention in the WFPB dietary intervention.
Time frame: 13 weeks, 26 weeks
Mean Change in Disease-Specific Quality of Life - FACT-B at 13 and 26 Weeks
Quality of life is assessed using the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire. Individual item scores are summed to create subscale scores and a total score, with higher scores indicating better quality of life. Mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Disease-Specific Quality of Life - FACT-En at 13 and 26 Weeks
Quality of life is assessed using the Functional Assessment of Cancer Therapy - Endocrine (FACT-En) questionnaire. Item responses are summed for subscales and a total score, with higher scores indicating better QOL. Mean change from baseline is evaluated.
Time frame: 13 weeks, 26 weeks
Mean Change in Cognitive Dysfunction (FACT-COG) at 13 and 26 Weeks
Cognitive function is measured using the FACT-COG questionnaire. Items are summed to generate a total cognitive dysfunction score. Higher scores indicate greater cognitive function (less dysfunction). Mean change from baseline is calculated to assess improvement or decline.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 13 weeks, 26 weeks
Mean Change in Cancer-Related Fatigue (BFI) at 13 and 26 Weeks
Fatigue is assessed using the Brief Fatigue Inventory (BFI). Scores for each item range from 0 (no fatigue) to 10 (severe fatigue) and are averaged to obtain a total fatigue score. Lower scores indicate less fatigue. Mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in General Symptoms (MDASI) at 13 and 26 Week
General symptoms are measured using the MD Anderson Symptom Inventory (MDASI). Items are rated 0-10, with higher scores indicating greater symptom severity. Total symptom burden is calculated by summing items. Mean change from baseline is evaluated to assess improvement.
Time frame: 13 weeks, 26 weeks
Overall Survival at Close of Study
Overall survival is defined as the time from study enrollment to death from any cause. Survival status is determined through medical records and follow-up.
Time frame: End of study (26 weeks)
Mean Change in Cardiometabolic Marker (Weight) at 13 and 26 Weeks
Weight is collected at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Cardiometabolic Marker (Lipids) at 13 and 26 Weeks
Lipids are measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Cardiometabolic Marker (Blood Pressure) at 13 and 26 Weeks
Blood Pressure is measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Cardiometabolic Marker (Insulin) at 13 and 26 Weeks
Insulin is measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Cardiometabolic Marker (Inflammation) at 13 and 26 Weeks
Inflammation is measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Cardiometabolic Marker (Blood Glucose) at 13 and 26 Weeks Description:
Blood Glucose is measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Hormonal Marker (IGF1) at 13 and 26 Weeks
Description: IGF1 is measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks
Mean Change in Hormonal Marker (sex hormones) at 13 and 26 Weeks
Sex hormones are measured at each time point, and mean change from baseline is calculated.
Time frame: 13 weeks, 26 weeks